Scientists have discovered that a potential new drug can reverse severe fatty liver disease in animal models by restoring gut ...

A common liver disease affecting nearly 30% of adults worldwide may be far more complicated than scientists previously ...

Researchers also identified associations between specific subtypes and conditions such as depression, sleep apnea and ...

For the first time, many people living with chronic hepatitis B may have a functional cure at hand. The US Food and Drug ...

The mechanisms that cause the world's most common chronic liver disease—metabolic dysfunction-associated steatotic liver ...

In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...

GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials.

GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to ...

Oct 20 (Reuters) - The US FDA said on Tuesday it had approved British drugmaker GSK's hepatitis B drug Hibsago, allowing ...

FDA-approved Hibsago could help some adults with chronic hepatitis B stop antiviral therapy. Learn who qualifies, what trials found, and the key risks.

"Start of a new era," says trial investigator ...

The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential. Bepirovirsen is specifically approved for patients ...